font size
Sign inprintPrint

DEALS:

Pharma to Support Early-Stage Biotechs

Roche and Bayer team with QB3 while Atlas Ventures rounds up Amgen and Novartis.


As Big Pharma continues to externalize its early stage R&D, it is ramping up its efforts to tap early stage innovation and support biotech startups that may eventually help fill its pipeline. Both Roche and Bayer announced that they will work with startup accelerator California Institute for Quantitative Biosciences, or QB3, to help identify, fund, and support early stage life science companies in the San Francisco Bay area. QB3 was established to create companies based on research conducted at the Universities of California Berkeley, San Francisco, and Santa Cruz. Read More
Other recent stories

Sign Up to recevie the Burrill Weekly Brief


Follow burrillreport on Twitter